ID   ME-F2
AC   CVCL_G313
SY   Me-F2
DR   cancercelllines; CVCL_G313
DR   Wikidata; Q54904906
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8018932;
RX   PubMed=21552520;
CC   Population: Japanese.
CC   Doubling time: 2-3 days (PubMed=8018932).
CC   Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_RL95 ! ME-2
SX   Male
AG   40Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 17
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8018932; DOI=10.1182/blood.V84.1.84.84;
RA   Yanagisawa K., Sato M., Horiuchi T., Hasegawa H., Fujita S.;
RT   "Difference in response to colony-stimulating factors and involvement
RT   of protein kinase C signal transduction system in three subclones from
RT   the ME-1 cell line and two sublines.";
RL   Blood 84:84-93(1994).
//
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169;
RA   Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A.,
RA   Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P.,
RA   Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.;
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:E19169-E19169(2011).
//